What is eviti?
eviti is a ground-breaking, comprehensive oncology clinical decision support platform,that, in real time, aligns the priorities of physicians, patients and payers through a transparent, independent, and holistic knowledge base of treatment options beyond clinical pathways – thus improving outcomes.
|eviti Introduction||About eviti, Inc.|
eviti Product Suite
From diagnosis through treatment plan selection, physician reimbursement and survivorship guidance, the eviti Suite oncology software provides advanced cancer patient care by aligning the priorities of physicians, patients and payers at the moment of clinical prescribing.
eviti Comprehensive, Non-biased Evidence-based
Medical Library (EBML)
eviti’s Evidence-Based Medical Library (EBML) is comprehensive, non-biased and independent. The data contained in the EBML is extremely granular and is used in the oncology decision support process to support the treatment plan selection algorithms within eviti. The EBML includes over 1,700 evidence-based treatment regimens and over 10,000 clinical trials for 120+ cancer types (as of 5/13). Regimens within the EBML address all tumor sites of origin (> 40), specific pathologic description (>600), stage (extent of tumor growth/spread), patient and tumor specific biomarkers, and prior therapy. Each regimen contains appropriate treatments (surgery, systemic therapy [chemotherapy, hormonal therapy, stem cell transplant] and/or radiotherapy) as warranted for the specific pathology and stage of the relevant cancer, data on the resulting clinical outcome and toxicities, and levels of medical evidence and support within the oncology community.
Regimens are added to, revised or inactivated within the EBML based on ongoing review of definitive trials presented in the peer-reviewed literature, major oncology meetings throughout the year and updates to guidelines produced by national government agencies (e.g. National Cancer Institute, Food and Drug Administration), national and international oncology professional organizations (e.g. American Society of Clinical Oncology, American Society of Hematology, American Society for Therapeutic Radiology and Oncology, American Urological Association, National Comprehensive Cancer Network and others) and consensus groups. This review and subsequent data entry is performed by a team within eviti, Inc. composed of advanced practice oncology nurses, a content information specialist and the eviti, Inc. Chief Medical Officer (and other members of the eviti, Inc. medical staff as needed). Once a regimen has been identified for addition to the EBML, data is abstracted from the relevant primary medical literature and then twice reviewed for quality by other team members. Any discrepancies found in review and audit are then reconciled. Beyond initial entry into the EBML, regimens are also reviewed throughout the year for continued relevance. All steps in this process are appropriately tracked and documented to ensure completion, accuracy, and adherence to eviti, Inc. protocols. All clinicians and staff who are responsible for researching, reviewing, entering and maintaining the data in the EBML are employees of eviti, Inc. and are not influenced by any third party organization or institution. eviti, Inc. and its employees have no financial interest in the treatments that are selected from the regimens displayed in eviti. eviti, Inc. receives no payments from any third party organization including pharmaceutical companies, drug wholesalers or medical device companies for the regimens that are included in the EBML.
Oncology Practices Registered with eviti
eviti has been deployed to over 2,000 oncology practices, representing 40% of all oncology practices nationwide; and on average, deviations from evidence-based medicine have dropped from 32% to less than 10%.
eviti Aligns Physicians, Patients and Payers Priorities
From diagnosis through cancer treatment plan selection, physician reimbursement and survivorship guidance, eviti’s approach to fighting cancer goes beyond oncology pathways.
eviti is an innovative technology that offers providers cancer guidelines and oncology solutions through real-time access to evidence-based standards and intelligence at the point of clinical prescribing. eviti provides the nation’s most comprehensive and unbiased digital library of evidence-based treatment regimens and cancer research available, taking into account cancer costs, outcomes, efficacy and toxicities. In addition, it includes over 1,700 of the most appropriate, proven cancer treatment options (as of 5/13) covering all modalities for more than 120 cancer types,meticulously compiled from the world’s leading sources.
eviti’s treatment knowledge base of oncology information and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent cancercare treatment plan review and selection process streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies to benefit all participants in the cancer treatment process, thus allowing the best cancer care to be available everywhere. eviti is a cancer disease management tool that can be used as a web-based application or as an integrated component within electronic health records software.
eviti’s robust library is carefully drawn from governmental data and industry sources, and is maintained by expert oncologists, a world-class medical advisory board, and other medical informatics professionals.
Never Before Have Payers Had This Level of Insight
eviti links evidence-based and other nationally accepted treatment plans with appropriate reimbursement using a unique eviti code. This innovative and efficient approach allows payers to offer automated precertification to all oncologists, along with streamlined reimbursement and improved productivity. Closing the loop with eviti’s pre-adjudication features streamlines the process, ensures quality, aligns payers with physicians and patients, and ultimately achieves the goal of appropriate payment for quality treatment. Never before have payers had this level of transparent insight into the risks and costs associated with cancer treatment support.
eviti’s open platform makes it easy to integrate with other oncology management solutions, including offerings from NantHealth’s Augmented IntelligenceTM